
Baclofen
CAS No. 1134-47-0
Baclofen ( Baclofen | Lioresal, Liofen, Gablofen | Baclon | Kemstro )
产品货号. M10468 CAS No. 1134-47-0
神经递质 GABA 的衍生物,充当 GABAB 受体激动剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
200MG | ¥251 | 有现货 |
![]() ![]() |
500MG | ¥373 | 有现货 |
![]() ![]() |
1G | ¥494 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Baclofen
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述神经递质 GABA 的衍生物,充当 GABAB 受体激动剂。
-
产品描述A derivative of the neurotransmitter GABA that acts as a GABAB receptor agonist; also blocks α2δ subunit-containing voltage-dependent calcium channel (VDCC) with Ki of 156 uM; A neurotransmitter inhibitor by blocking the release of excitatory transmitters; serves as a central nervous system depressant and skeletal muscle relaxant.Other Indication Approved(In Vitro):Baclofen (1, 10 μM; 24 h) causes markedly decreased lactate dehydrogenase (LDH) activity, indicating increased cell viability in wild-type or mutant huntingtin-expressing striatal cells (HD19 or HD43). Baclofen significantly increases chymotrypsin-like proteasome activity and cell viability were in the HD43 cells.(In Vivo):Baclofen (i.p.; 10 μg/g; twice daily for 3 consecutive days) ameliorates motor deficits in YAC128 HD transgenic mice.
-
体外实验——
-
体内实验Animal Model:Wild type (WT) and mutant (MT) male YAC128 mice at 13-18 months of age Dosage:10 μg/g Administration:IP; twice daily at 9:00 a.m. and 5:00 p.m., for 3 consecutive days; then single dose on the fourth day at 9:00 a.m Result:Ameliorated motor deficits in YAC128 HD transgenic mice. Increased proteasome activity and reduces neuronal intranuclear inclusions (NIIs) in YAC128 HD transgenic mice.
-
同义词Baclofen | Lioresal, Liofen, Gablofen | Baclon | Kemstro
-
通路Membrane Transporter/Ion Channel
-
靶点GAT
-
受体GABAR
-
研究领域Other Indications
-
适应症Other Disease
化学信息
-
CAS Number1134-47-0
-
分子量213.6608
-
分子式C10H12ClNO2
-
纯度>98% (HPLC)
-
溶解度DMSO: < 7.8 mg/mL
-
SMILESO=C(O)CC(C1=CC=C(Cl)C=C1)CN
-
化学全称Benzenepropanoic acid, β-(aminomethyl)-4-chloro-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zvejniece L, et al. Pharmacol Biochem Behav. 2015 Oct;137:23-9.
2. Carter LP, et al. Pharmacol Ther. 2009 Jan;121(1):100-14.